Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0108 USD
−4.52 M USD
0.00 USD
187.46 M
About Oncotelic Therapeutics, Inc.
Sector
Industry
CEO
Vuong Trieu
Website
Headquarters
Agoura Hills
Founded
1988
FIGI
BBG000BJ2VZ6
Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of OTLC is 0.0521 USD — it has decreased by −5.44% in the past 24 hours. Watch Oncotelic Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Oncotelic Therapeutics, Inc. stocks are traded under the ticker OTLC.
OTLC stock has fallen by −11.24% compared to the previous week, the month change is a −6.13% fall, over the last year Oncotelic Therapeutics, Inc. has showed a 41.19% increase.
OTLC reached its all-time high on Sep 5, 1997 with the price of 10,050.0000 USD, and its all-time low was 0.0100 USD and was reached on Jun 27, 2023. View more price dynamics on OTLC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
OTLC stock is 15.04% volatile and has beta coefficient of −0.26. Track Oncotelic Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Oncotelic Therapeutics, Inc. there?
Today Oncotelic Therapeutics, Inc. has the market capitalization of 21.27 M, it has increased by 5.58% over the last week.
Yes, you can track Oncotelic Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Oncotelic Therapeutics, Inc. is going to release the next earnings report on Aug 25, 2025. Keep track of upcoming events with our Earnings Calendar.
OTLC net income for the last quarter is −298.72 K USD, while the quarter before that showed −600.93 K USD of net income which accounts for 50.29% change. Track more Oncotelic Therapeutics, Inc. financial stats to get the full picture.
No, OTLC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 18, 2025, the company has 40 employees. See our rating of the largest employees — is Oncotelic Therapeutics, Inc. on this list?
Like other stocks, OTLC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oncotelic Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oncotelic Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oncotelic Therapeutics, Inc. stock shows the neutral signal. See more of Oncotelic Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.